Shares of Teva Pharmaceutical Industries are once again trading at an historic high. But they might not be there today if it weren’t for a tragedy.
Hospitals and drug makers, which supported the final healthcare legislation, would be clear beneficiaries, analysts say, even if the outlook for insurers was less certain, the NY Times reports.
The 800-pound gorilla of one industry has beaten the 800-pound gorilla of another. Teva CEO Shlomo Yanai took on Pfizer CEO Jeff Kindler and won.
Take our quiz and see how much you know about products that were recalled to keep consumers safe.
Speaker Pelosi is as good as it gets in wrestling votes for legislation she favors. She is the female version of that titan, Tip O'Neill (D. Mass.) who famously said, "All politics is local." But as good as she is, the Speaker seems to have come up short with the necessary votes to get the Senate version of the health care bill passed in the House of Representatives.
I can hear the commercial now. “Underarm protection that literally makes you feel more like a man.”
With states squeezing payments to providers even as the economy fuels explosive growth in enrollment, patients are finding it increasingly difficult to locate doctors and dentists who will accept Medicaid coverage. The New York Times reports.
Of course, I'm off the day all heck breaks loose on the beat and stocks are making big moves all over the place.
President Obama is going all in on the health care plan. He postponed an overseas trip to be on hand for a hoped for vote on the plan this coming Friday.
Tomorrow is the day the agency is scheduled to announce if the first once-a-week diabetes treatment, a rejiggered version of the now twice-a-day Byetta, can come to market.
A unit of Johnson & Johnson, just months after saying it was phasing out an artificial hip implant because of slowing sales, has warned doctors that the device appears to have a high early failure rate in some patients.
On the eve of the 10-year anniversary of the dot-com bubble bursting the stock stat mavens here at CNBC sliced and diced all sorts of data on share price performance since March 10, 2000.
It's not quite the same as waiting for new, entertaining commercials during the Super Bowl, but there was a noteworthy premiere during last night's Academy Awards.
This morning, BMO Capital Markets biotech analyst Jason Zhang downgraded shares of Amylin Pharmaceuticals to the equivalent of "Sell."
President Obama has high cholesterol. For now, his doctors are prescribing healthy living. But some say he should be put on a statin or cholesterol-lowering drug pronto.
Shares of Dendreon fell around 10 percent before the market opened. And now, in regular trading, they're at a new intra-day high. Here's what happened.
When a major pharma company holds analyst/investor meetings as infrequently as Bristol-Myers Squibb, it's kind of a must-cover event.
The Food and Drug Administration says its decisions are always based on the science. But on rare occasions ol' mother nature apparently can get in the way.
On day five of Avandiagate, GlaxoSmithKline communiques about the brouhaha surrounding the controversial diabetes drug now number six.
The company is suing more than half a dozen generic drug firms that want to make a cheaper copy of Crestor years before the patent on the drug is set to expire. But you won't find me sitting in the pews furiously taking notes.